Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting

Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting

Read more

CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)

BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.

Read more

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.

Read more